Arthritis Research & Therapy

official impact factor 4.36

This article is part of the supplement: Basic science, rationale, background and future of denosumab: a RANK ligand inhibitor

Highly Access

Tumor metastasis to bone

Mandeep S Virk and Jay R Lieberman*

Arthritis Research & Therapy 2007, 9(Suppl 1):S5 doi:10.1186/ar2169

Accesses  

  • Last 30 days: 159 accesses
  • Last 365 days: 1374 accesses
  • All time: 7522 accesses